Izun Pharmaceuticals Corp Appoints Jack Talley as Chief Executive Officer
July 22, 2015
Izun Pharmaceuticals Corporation, a clinical stage company focused on developing high efficacy products based on compounds derived from botanical sources announced today that it has appointed Jack Talley as its Chief Executive Officer.
Mr. Talley brings over 30 years of relevant experience in the pharmaceutical industry, fifteen of which were as CEO in emerging pharmaceutical companies. Most recently, Mr. Talley was CEO and President of Alissa Pharma, a company focusing on radioimmunotherapy utilizing novel targeted antibodies in the treatment of solid tumors. Prior to that he was the CEO and President of EpiCept where he oversaw the establishment of EpiCept as a public company. During his tenure, Mr. Talley successfully raised in excess of $100 million for the company and secured licenses for a number of its products. Mr. Talley also served as CEO and President for Consensus Pharmaceuticals, President and Chief Operating Officer of Penwest Pharmaceuticals Company where he established an alliance with Endo Pharmaceuticals, which provided the foundation for the acquisition of Penwest by Endo and a Vice President of Marketing at Sanofi.
Dr. Bill Levine, the founder and previous CEO of Izun, who has now assumed the role of Executive Chairman stated, “Jack brings invaluable expertise in both drug development and product commercialization to Izun. His leadership skills, breadth of knowledge of the industry, commercialization experience, proven interaction with regulatory bodies as well as successes in capital raising will surely be a tremendous asset to Izun.”
Mr. Talley commented, “I am very excited to join the team at Izun. The Company has an exciting portfolio of pipeline products that are poised to deliver substantial benefits to patients and therefore shareholder value. Izun’s unique ability to harness the power of botanical products coupled with a potentially favorable regulatory pathway is particularly attractive. The ongoing clinical programs are expected to deliver near term milestones that will fuel growth for the Company at this transformative stage.”